Antiretroviral therapy initiation before during or after pregnancy in HIV-1-infected women: Maternal virologic immunologic and clinical response

PLoS ONE

Volumn 4, Issue 9, 2009, Pages

  Melekhin, Vlada V ^a   Shepherd, Bryan E ^b   Stinnette, Samuel E ^a   Rebeiro, Peter F ^a   Barkanic, Gema ^a   Raffanti, Stephen P ^a,c   Sterling, Timothy R ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c Comprehensive Care Center ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MORTALITY; PREGNANCY; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; CD4 LYMPHOCYTE COUNT; DISEASE TRANSMISSION; ENVIRONMENTAL EXPOSURE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; METHODOLOGY; MULTIVARIATE ANALYSIS; TIME; TREATMENT OUTCOME;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MATERNAL EXPOSURE; MULTIVARIATE ANALYSIS; PREGNANCY; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 70149090604     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0006961     Document Type: Article

References (56)

1. United Nations Joint Programme on HIV/AIDS. (2008) 2007 AIDS epidemic update. Available at http://www.unaids.org/en/. Accessed 20 July, 2009.
2. Perinatal HIV Guidelines Working Group. (July 8, 2008) Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIVInfected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. Available at http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf. Accessed 20 July, 2009. pp 1-98.
3. Achievements in public health. (2006) Reduction in perinatal transmission of HIV infection-United States, 1985-2005. MMWR Morb Mortal Wkly Rep 55: 592-597.
4. Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, et al. (2002) Combination antiretroviral strategies for the treatment of pregnant HIV-1infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 29: 484-494.
5. Scott GB, Fischl MA, Klimas N, Fletcher MA, Dickinson GM, et al. (1985) Mothers of infants with the acquired immunodeficiency syndrome. Evidence for both symptomatic and asymptomatic carriers. JAMA 253: 363-366.
6. Minkoff H, Nanda D, Menez R, Fikrig S (1987) Pregnancies resulting in infants with acquired immunodeficiency syndrome or AIDS-related complex. Obstet Gynecol 69: 285-287.
7. Biggar RJ, Pahwa S, Minkoff H, Mendes H, Willoughby A, et al. (1989) Immunosuppression in pregnant women infected with human immunodeficiency virus. Am J Obstet Gynecol 161: 1239-1244.
8. Deschamps MM, Pape JW, Desvarieux M, Williams-Russo P, Madhavan S, et al. (1993) A prospective study of HIV-seropositive asymptomatic women of childbearing age in a developing country. J Acquir Immune Defic Syndr 6: 446-451.
9. Kumar RM, Uduman SA, Khurranna AK (1995) Impact of maternal HIV-1 infection on perinatal outcome. Int J Gynaecol Obstet 49: 137-143.
10. Hocke C, Morlat P, Chene G, Dequae L, Dabis F (1995) Prospective cohort study of the effect of pregnancy on the progression of human immunodeficiency virus infection. The Groupe d'Epidemiologie Clinique Du SIDA en Aquitaine. Obstet Gynecol 86: 886-891.
11. Alliegro MB, Dorrucci M, Phillips AN, Pezzotti P, Boros S, et al. (1997) Incidence and consequences of pregnancy in women with known duration of HIV infection. Italian Seroconversion Study Group. Arch Intern Med 157: 2585-2590.
12. Bessinger R, Clark R, Kissinger P, Rice J, Coughlin S (1998) Pregnancy is not associated with the progression of HIV disease in women attending an HIV outpatient program. Am J Epidemiol 147: 434-440.
13. Weisser M, Rudin C, Battegay M, Pfluger D, Kully C, et al. (1998) Does pregnancy influence the course of HIV infection? Evidence from two large Swiss cohort studies. J Acquir Immune Defic Syndr Hum Retrovirol 17: 404-410.
14. Saada M, Le Chenadec J, Berrebi A, Bongain A, Delfraissy JF, et al. (2000) Pregnancy and progression to AIDS: results of the French prospective cohorts. SEROGEST and SEROCO Study Groups. AIDS 14: 2355-2360.
15. Brocklehurst P, French R (1998) The association between maternal HIV infection and perinatal outcome: a systematic review of the literature and metaanalysis. Br J Obstet Gynaecol 105: 836-848.
16. Tai JH, Udoji MA, Barkanic G, Byrne DW, Rebeiro PF, et al. (2007) Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy. J Infect Dis 196: 1044-1052.
17. Kramer MS, Platt RW, Wen SW, Joseph KS, Allen A, et al. (2001) A new and improved population-based Canadian reference for birth weight for gestational age. Pediatrics 108: E35.
18. Dietz PM, England LJ, Callaghan WM, Pearl M, Wier ML, et al. (2007) A comparison of LMP-based and ultrasound-based estimates of gestational age using linked California livebirth and prenatal screening records. Paediatr Perinat Epidemiol 21 Suppl 2: 62-71.
19. Savitz DA, Terry JW, Jr., Dole N, Thorp JM, Jr., Siega-Riz AM, et al. (2002) Comparison of pregnancy dating by last menstrual period, ultrasound scanning, and their combination. Am J Obstet Gynecol 187: 1660-1666.
20. Waller DK, Spears WD, Gu Y, Cunningham GC (2000) Assessing numberspecific error in the recall of onset of last menstrual period. Paediatr Perinat Epidemiol 14: 263-267.
21. Somerset DA, Zheng Y, Kilby MD, Sansom DM, Drayson MT (2004) Normal human pregnancy is associated with an elevation in the immune suppressive CD25+ CD4+ regulatory T-cell subset. Immunology 112: 38-43.
22. Sanchez-Ramon S, Navarro AJ, Aristimuno C, Rodriguez-Mahou M, Bellon JM, et al. (2005) Pregnancy-induced expansion of regulatory T-lymphocytes may mediate protection to multiple sclerosis activity. Immunol Lett 96: 195-201.
23. Centers for Disease Control and Prevention. (1992) 1993 revised classification system for HIV infection and expanded surveillance care definition for AIDS among adolescents and adults. MMWR Recomm Rep 41(RR-17): 1-19.
24. Laird NM, Ware JH (1982) Random-effects models for longitudinal data. Biometrics 38: 963-974.
25. Golub ET, Benning L, Sharma A, Gandhi M, Cohen MH, et al. (2008) Patterns, predictors, and consequences of initial regimen type among HIV-infected women receiving highly active antiretroviral therapy. Clin Infect Dis 46: 305-312.
26. Kuritzkes DR, Ribaudo HJ, Squires KE, Koletar SL, Santana J, et al. (2007) Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s. J Infect Dis 195: 1169-1176.
27. Perez-Elias MJ, Moreno A, Moreno S, Lopez D, Antela A, et al. (2005) Higher virological effectiveness of NNRTI-based antiretroviral regimens containing nevirapine or efavirenz compared to a triple NRTI regimen as initial therapy in HIV-1-infected adults. HIV Clin Trials 6: 312-319.
28. Rubin DB (1997) Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127: 757-763.
29. Modjarrad K, Chamot E, Vermund SH (2008) Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression. AIDS 22: 2179-2185.
30. Arrive E, Newell ML, Ekouevi DK, Chaix ML, Thiebaut R, et al. (2007) Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol 36: 1009-1021.
31. Chaix ML, Ekouevi DK, Rouet F, Tonwe-Gold B, Viho I, et al. (2006) Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire. J Infect Dis 193: 482-487.
32. Giuliano M, Palmisano L, Galluzzo CM, Amici R, Germinario E, et al. (2003) Selection of resistance mutations in pregnant women receiving zidovudine and lamivudine to prevent HIV perinatal transmission. AIDS 17: 1570-1572.
33. Fingerhut LA, Kleinman JC, Kendrick JS (1990) Smoking before, during, and after pregnancy. Am J Public Health 80: 541-544.
34. Ebrahim SH, Floyd RL, Merritt RK 2nd, Decoufle P, Holtzman D (2000) Trends in pregnancy-related smoking rates in the United States, 1987-1996. JAMA 283: 361-366.
35. Vaz MJ, Barros SM, Palacios R, Senise JF, Lunardi L, et al. (2007) HIV-infected pregnant women have greater adherence with antiretroviral drugs than non-pregnant women. Int J STD AIDS 18: 28-32.
36. Bardeguez AD, Lindsey JC, Shannon M, Tuomala RE, Cohn SE, et al. (2008) Adherence to antiretrovirals among US women during and after pregnancy. J Acquir Immune Defic Syndr 48: 408-417.
37. Mellins CA, Chu C, Malee K, Allison S, Smith R, et al. (2008) Adherence to antiretroviral treatment among pregnant and postpartum HIV-infected women. AIDS Care 20: 958-968.
38. Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, et al. (2000) Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 14: 357-366.
39. Arnsten JH, Demas PA, Farzadegan H, Grant RW, Gourevitch MN, et al. (2001) Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis 33: 1417-1423.
40. Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, et al. (2001) Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 15: 1181-1183.
41. Hogg RS, Heath K, Bangsberg D, Yip B, Press N, et al. (2002) Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS 16: 1051-1058.
42. Thea DM, Steketee RW, Pliner V, Bornschlegel K, Brown T, et al. (1997) The effect of maternal viral load on the risk of perinatal transmission of HIV-1. New York City Perinatal HIV Transmission Collaborative Study Group. AIDS 11: 437-444.
43. Polanczyk MJ, Carson BD, Subramanian S, Afentoulis M, Vandenbark AA, et al. (2004) Cutting edge: estrogen drives expansion of the CD4+CD25+ regulatory T cell compartment. J Immunol 173: 2227-2230.
44. Belkaid Y, Rouse BT (2005) Natural regulatory T cells in infectious disease. Nat Immunol 6: 353-360.
45. Effros RB (2003) Replicative senescence: the final stage of memory T cell differentiation? Curr HIV Res 1: 153-165.
46. Panel on Antiretroviral Guidelines for Adult and Adolescents. (November 3, 2008) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf. Accessed 20 July, 2009. pp 1-139.
47. Kaufmann GR, Bloch M, Zaunders JJ, Smith D, Cooper DA (2000) Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy. AIDS 14: 959-969.
48. Lucas GMGK, Chaisson RE, et al. (2002) Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS 16: 767-774.
49. Dronda F, Zamora J, Moreno S, Moreno A, Casado JL, et al. (2004) CD4 cell recovery during successful antiretroviral therapy in naive HIV-infected patients: the role of intravenous drug use. AIDS 18: 2210-2212.
50. Cheng DM, Nunes D, Libman H, Vidaver J, Alperen JK, et al. (2007) Impact of hepatitis C on HIV progression in adults with alcohol problems. Alcohol Clin Exp Res 31: 829-836.
51. Kakehasi FM, Tupinambas U, Cleto S, Aleixo A, Lin E, et al. (2007) Persistence of genotypic resistance to nelfinavir among women exposed to prophylactic antiretroviral therapy during pregnancy. AIDS Res Hum Retroviruses 23: 1515-1520.
52. Eastman PS, Shapiro DE, Coombs RW, Frenkel LM, McSherry GD, et al. (1998) Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in pediatric AIDS Clinical Trials Group Protocol 076. J Infect Dis 177: 557-564.
53. Kully C, Yerly S, Erb P, Kind C, Krautheim A, et al. (1999) Codon 215 mutations in human immunodeficiency virus-infected pregnant women. Swiss Collaborative 'HIV and Pregnancy' Study. J Infect Dis 179: 705-708.
54. Welles SL, Pitt J, Colgrove R, McIntosh K, Chung PH, et al. (2000) HIV-1 genotypic zidovudine drug resistance and the risk of maternal-infant transmission in the women and infants transmission study. The Women and Infants Transmission Study Group. AIDS 14: 263-271.
55. Ekpini RA, Nkengasong JN, Sibailly T, Maurice C, Adje C, et al. (2002) Changes in plasma HIV-1-RNA viral load and CD4 cell counts, and lack of zidovudine resistance among pregnant women receiving short-course zidovudine. AIDS 16: 625-630.
56. Bardeguez AD, Shapiro DE, Mofenson LM, Coombs R, Frenkel LM, et al. (2003) Effect of cessation of zidovudine prophylaxis to reduce vertical transmission on maternal HIV disease progression and survival. J Acquir Immune Defic Syndr 32: 170-181.